Cover Image
市場調查報告書

全球多發性硬化症:患者數及市場規模的預測

Global Multiple Sclerosis Market, Patient Numbers & Forecast (By Mode of Administration: Injectables Market, Infusions Market, Orals Market) - Actual & Unmet (Potential)

出版商 Renub Research 商品編碼 557387
出版日期 內容資訊 英文 108 Pages; 93 Figures; 1 Table
商品交期: 最快1-2個工作天內
價格
Back to Top
全球多發性硬化症:患者數及市場規模的預測 Global Multiple Sclerosis Market, Patient Numbers & Forecast (By Mode of Administration: Injectables Market, Infusions Market, Orals Market) - Actual & Unmet (Potential)
出版日期: 2017年09月15日 內容資訊: 英文 108 Pages; 93 Figures; 1 Table
簡介

全球多發性硬化症的市場呈穩定成長態勢,預計2022年超越200億美元的規模。

本報告提供全球多發性硬化症的市場調查,患者數及市場規模的變化與預測,潛在患者及潛在的市場規模的變化與預測,投藥途徑及各主要國家的詳細分析,市場促進因素及課題分析等彙整資料。

第1章 調查結果

第2章 全球患者數的變化、預測

  • 患者數、預測
  • 病理修飾療法 (DMT)的患者數、預測
  • 患者數、預測:各投藥途徑
    • 注射
    • 點滴
    • 口服

第3章 全球市場規模的變化、預測

  • 潛在市場規模、預測
  • 實在市場規模、預測
  • 投藥各途徑的規模、預測
    • 注射
    • 點滴
    • 口服

第4章 患者數的佔有率:變化與預測

  • 患者數的佔有率、預測:各國
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 美國
  • 病理修飾療法 (DMT)的患者數的佔有率、預測:各國
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 美國
  • 患者數的佔有率、預測:各投藥途徑
    • 注射
    • 點滴
    • 口服

第5章 市場規模的佔有率:變化與預測

  • 潛在市場:各國
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 美國
  • 實在市場:各國
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 美國
  • 各投藥途徑
    • 注射
    • 點滴
    • 口服

第6章 英國

  • 患者數的變化與預測
    • 患者數、預測
    • 病理修飾療法 (DMT) 患者數、預測
  • 市場規模的變化與預測
    • 潛在市場、預測
    • 市場、預測

第7章 法國

  • 患者數的變化與預測
    • 患者數、預測
    • 病理修飾療法 (DMT) 患者數、預測
  • 市場規模的變化與預測
    • 潛在市場、預測
    • 市場、預測

第8章 德國

  • 患者數的變化與預測
    • 患者數、預測
    • 病理修飾療法 (DMT) 患者數、預測
  • 市場規模的變化與預測
    • 潛在市場、預測
    • 市場、預測

第9章 義大利

  • 患者數的變化與預測
    • 患者數、預測
    • 病理修飾療法 (DMT) 患者數、預測
  • 市場規模的變化與預測
    • 潛在市場、預測
    • 市場、預測

第10章 西班牙

  • 患者數的變化與預測
    • 患者數、預測
    • 病理修飾療法 (DMT) 患者數、預測
  • 市場規模的變化與預測
    • 潛在市場、預測
    • 市場、預測

第11章 美國

  • 患者數的變化與預測
    • 患者數、預測
    • 病理修飾療法 (DMT) 患者數、預測
  • 市場規模的變化與預測
    • 潛在市場、預測
    • 市場、預測

第12章 成長推動因素

第13章 課題

第14章 附錄

目錄

Global multiple sclerosis market is steadily growing and it is expected to cross over US$ 20 Billion landmark by 2022. Multiple sclerosis market is one of the most common neurological disorder diseases in the world. It is estimated that global multiple sclerosis patient numbers will increase around 35 Thousand by 2022. According to Renub Research analysis, we have found that there is huge gap between actual and unmet market as disease modifying therapy receiving prevalence vary from country to country. Global multiple sclerosis unmet market is much higher compared to its actual market.

Reimbursement is key growth driver for Multiple Sclerosis market globally

Reimbursement is playing major role for the growth of multiple sclerosis market as multiple sclerosis drugs are too expensive and without reimbursement, it is nearly impossible to afford the treatment of MS by most of the multiple sclerosis patient in the world. Most of the European and North American countries have multiple sclerosis reimbursement policy; however eligibility criteria vary from country to country.

Multiple Sclerosis Drugs price is too expensive

Multiple sclerosis drugs price is steadily increasing which create a major challenge for the growth of multiple sclerosis market in the world. It is estimated that newly launched multiple sclerosis drugs are expensive than previous generation disease modifying drugs. According to our research, we have found that, United States multiple sclerosis drugs are nearly five times higher than European multiple sclerosis drugs price.

Injectables Disease Modifying Therapy Multiple Sclerosis Market is losing Ground

Injectables disease modifying therapy multiple sclerosis market is continuously declining. Newly launched orals disease modifying therapy is a growing market.

‘Global Multiple Sclerosis Market, Patient Numbers & Forecast (By Mode of Administration: Injectables Market, Infusions Market, Orals Market) - Actual & Unmet (Potential) ’published by Renub Research on Multiple Sclerosis Market. This 108 page report with 93 figures and 1 Tables provides 6 Countries: actual and potential/unmet patient numbers and market. This report also explains multiple sclerosis disease modifying therapy (DMT) mode of administration.

  • Actual Market is the current market which is already present
  • Unmet Market is the market which can be accomplished; but it has yet not been accomplished due to demand and supply gap. At present DMT receiving patients are less than total number of multiple sclerosis patient numbers.

6 Countries Multiple Sclerosis Market & Patients Treated Studied in the Report is as Follows:

  • 1. United States
  • 2. United Kingdom
  • 3. Germany
  • 4. France
  • 5. Italy
  • 6. Spain

Worldwide and United States Multiple Sclerosis Market & Patients Treated by Mode of administration

  • 1. Injectables
  • 2. Infusions
  • 3. Orals

Key Questions Answered in the Report?

  • What is multiple sclerosis market globally and its growth potential in Future?
  • How many number of patients treated by disease modifying therapy globally?
  • What is the multiple sclerosis market in United States and other European countries?
  • How many number of multiple sclerosis patients living in United States and other European countries?

Table of Contents

1. Research Findings

2. Global Multiple Sclerosis Patient Numbers (2011 - 2022)

  • 2.1. Patient Number & Forecast
  • 2.2. Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
  • 2.3. By Mode of Administration - Injectables, Infusion, Oral Patient Numbers & Forecast
    • 2.3.1. Injectables
    • 2.3.2. Infusions
    • 2.3.3. Orals

3. Global Multiple Sclerosis Market (2011 - 2022)

  • 3.1. Unmet Market & Forecast
  • 3.2. Market & Forecast
  • 3.3. By Mode of Administration - Injectables, Infusions, Orals Market & Forecast
    • 3.3.1. Injectables Market
    • 3.3.2. Infusions Market
    • 3.3.3. Orals Market

4. Patient Share - Global Multiple Sclerosis (2011 - 2022)

  • 4.1. Patient Numbers Share & Forecast - (UK, France, Germany, Italy, Spain & United States)
  • 4.2. Disease-Modifying Therapy (DMT) - (UK, France, Germany, Italy, Spain & United States)
  • 4.3. By Mode of Administration - Injectables, Infusion, Oral

5. Market Share - Global Multiple Sclerosis (2011 - 2022)

  • 5.1. Unmet Market Share & Forecast - (UK, France, Germany, Italy, Spain & United States)
  • 5.2. Market Share & Forecast - (UK, France, Germany, Italy, Spain & United States)
  • 5.3. By Mode of Administration - Injectables, Infusion, Oral

6. United Kingdom

  • 6.1. Multiple Sclerosis Patient Numbers (2011 - 2022)
    • 6.1.1. Patient Number & Forecast
    • 6.1.2. Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
  • 6.2. Multiple Sclerosis Market (2011 - 2022)
    • 6.2.1. Unmet Market & Forecast
    • 6.2.2. Market & Forecast

7. France

  • 7.1. Multiple Sclerosis Patient Number (2011 - 2022)
    • 7.1.1. Patient Number & Forecast
    • 7.1.2. Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
  • 7.2. Multiple Sclerosis Market (2011 - 2022)
    • 7.2.1. Unmet Market & Forecast
    • 7.2.2. Market & Forecast

8. Germany

  • 8.1. Multiple Sclerosis Patient Number (2011 - 2022)
    • 8.1.1. Patient Number & Forecast
    • 8.1.2. Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
  • 8.2. Multiple Sclerosis Market (2011 - 2022)
    • 8.2.1. Unmet Market & Forecast
    • 8.2.2. Market & Forecast

9. Italy

  • 9.1. Multiple Sclerosis Patient Number (2011 - 2022)
    • 9.1.1. Patient Number & Forecast
    • 9.1.2. Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
  • 9.2. Multiple Sclerosis Market (2011 - 2022)
    • 9.2.1. Unmet Market & Forecast
    • 9.2.2. Market & Forecast

10. Spain

  • 10.1. Multiple Sclerosis Patient Number (2011 - 2022)
    • 10.1.1. Patient Number & Forecast
    • 10.1.2. Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
  • 10.2. Multiple Sclerosis Market (2011 - 2022)
    • 10.2.1. Unmet Market & Forecast
    • 10.2.2. Market & Forecast

11. United States

  • 11.1. Multiple Sclerosis Patient Numbers (2011 - 2022)
    • 11.1.1. Patient Number & Forecast
    • 11.1.2. Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
  • 11.2. By Mode of Administration
    • 11.2.1. Injectables Patients Numbers
    • 11.2.2. Infusions Patients Numbers
    • 11.2.3. Orals Patient Numbers
  • 11.3. United States Multiple Sclerosis Market (2011 - 2022)
    • 11.3.1. Unmet Market & Forecast
    • 11.3.2. Market & Forecast
  • 11.4. By Mode of Administration
    • 11.4.1. Injectables Market
    • 11.4.2. Infusions Market
    • 11.4.3. Orals Market

12. Growth Drivers (Due to data confidentiality, growth factors have not been disclosed in this table of contents)

  • 12.1. Point no. 1
  • 12.2. Point no. 2

13. Challenges (Due to data confidentiality, challenges have not been disclosed in this table of contents)

  • 13.1. Point no. 1
  • 13.2. Point no. 2
  • 13.3. Point no. 3

14. Appendix

List of Figures

  • Figure 2-1: Global - Multiple Sclerosis Patient Numbers (Thousand), 2011 - 2016
  • Figure 2-2: Global - Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 - 2022
  • Figure 2-3: Global - Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 - 2016
  • Figure 2-4: Global - Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 - 2022
  • Figure 2-5: Global - Multiple Sclerosis Injectables Patient Numbers (Thousand), 2011 - 2016
  • Figure 2-6: Global - Forecast for Multiple Sclerosis Injectables Patient Numbers (Thousand), 2017 - 2022
  • Figure 2-7: Global - Multiple Sclerosis Infusions Patient Numbers (Thousand), 2011 - 2016
  • Figure 2-8: Global - Forecast for Multiple Sclerosis Infusions Patient Numbers (Thousand), 2017 - 2022
  • Figure 2-9: Global - Multiple Sclerosis Orals Patient Numbers (Thousand), 2011 - 2016
  • Figure 2-10: Global - Forecast for Multiple Sclerosis Orals Patient Numbers (Thousand), 2017 - 2022
  • Figure 3-1: Global - Multiple Sclerosis Unmet Market (Billion US$), 2011 - 2016
  • Figure 3-2: Global - Forecast for Multiple Sclerosis Unmet Market (Billion US$), 2017 - 2022
  • Figure 3-3: Global - Multiple Sclerosis Market (Billion US$), 2011 - 2016
  • Figure 3-4: Global - Forecast for Multiple Sclerosis Market (Billion US$), 2017 - 2022
  • Figure 3-5: Global - Multiple Sclerosis Injectables Market (Million US$), 2011 - 2016
  • Figure 3-6: Global - Forecast for Multiple Sclerosis Injectables Market (Million US$), 2017 - 2022
  • Figure 3-7: Global - Multiple Sclerosis Infusions Market (Million US$), 2011 - 2016
  • Figure 3-8: Global - Forecast for Multiple Sclerosis Infusions Market (Million US$), 2017 - 2022
  • Figure 3-9: Global - Multiple Sclerosis Orals Market (Million US$), 2011 - 2016
  • Figure 3-10: Global - Forecast for Multiple Sclerosis Orals Market (Million US$), 2017 - 2022
  • Figure 4-1: Global - Patient Numbers Share (Percent), 2011 - 2016
  • Figure 4-2: Global - Forecast for Patient Numbers Share (Percent), 2017 - 2022
  • Figure 4-3: Global - Disease-Modifying Therapy (DMT) Patient Numbers Share (Percent), 2011 - 2016
  • Figure 4-4: Global - Forecast for Disease-Modifying Therapy (DMT) Patient Numbers Share (Percent), 2017 - 2022
  • Figure 4-5: Global - Multiple Sclerosis Mode of Administration Patient Numbers Share (Percent), 2011 - 2016
  • Figure 4-6: Global - Forecast for Multiple Sclerosis Mode of Administration Patient Numbers Share (Percent), 2017 - 2022
  • Figure 4-7: Global - Multiple Sclerosis Unmet Market Share (Percent), 2011 - 2016
  • Figure 4-8: Global - Forecast for Multiple Sclerosis Unmet Market Share (Percent), 2017 - 2022
  • Figure 4-9: Global - Multiple Sclerosis Market Share (Percent), 2011 - 2016
  • Figure 4-10: Global - Forecast for Multiple Sclerosis Market Share (Percent), 2017 - 2022
  • Figure 4-11: Global - Multiple Sclerosis Market by Mode of Administration Share (Percent), 2011 - 2016
  • Figure 4-12: Global - Forecast for Multiple Sclerosis Market by Mode of Administration Share (Percent), 2017 - 2022
  • Figure 5-1: United Kingdom - Multiple Sclerosis Patient Numbers (Thousand), 2011 - 2016
  • Figure 5-2: United Kingdom - Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 - 2022
  • Figure 5-3: United Kingdom - Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 - 2016
  • Figure 5-4: United Kingdom - Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 - 2022
  • Figure 5-5: United Kingdom - Multiple Sclerosis Unmet Market (Million US$), 2011 - 2016
  • Figure 5-6: United Kingdom - Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 - 2022
  • Figure 5-7: United Kingdom - Multiple Sclerosis Market (Million US$), 2011 - 2016
  • Figure 5-8: United Kingdom - Forecast for Multiple Sclerosis Market (Million US$), 2017 - 2022
  • Figure 6-1: France - Multiple Sclerosis Patient Numbers (Thousand), 2011 - 2016
  • Figure 6-2: France - Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 - 2022
  • Figure 6-3: France - Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 - 2016
  • Figure 6-4: France - Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 - 2022
  • Figure 6-5: France - Multiple Sclerosis Unmet Market (Million US$), 2011 - 2016
  • Figure 6-6: France - Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 - 2022
  • Figure 6-7: France - Multiple Sclerosis Market (Million US$), 2011 - 2016
  • Figure 6-8: France - Forecast for Multiple Sclerosis Market (Million US$), 2017 - 2022
  • Figure 7-1: Germany - Multiple Sclerosis Patient Numbers (Thousand), 2011 - 2016
  • Figure 7-2: Germany - Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 - 2022
  • Figure 7-3: Germany - Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 - 2016
  • Figure 7-4: Germany - Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 - 2022
  • Figure 7-5: Germany - Multiple Sclerosis Unmet Market (Million US$), 2011 - 2016
  • Figure 7-6: Germany - Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 - 2022
  • Figure 7-7: Germany - Multiple Sclerosis Market (Million US$), 2011 - 2016
  • Figure 7-8: Germany - Forecast for Multiple Sclerosis Market (Million US$), 2017 - 2022
  • Figure 8-1: Italy - Multiple Sclerosis Patient Numbers (Thousand), 2011 - 2016
  • Figure 8-2: Italy - Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 - 2022
  • Figure 8-3: Italy - Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 - 2016
  • Figure 8-4: Italy - Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 - 2022
  • Figure 8-5: Italy - Multiple Sclerosis Unmet Market (Million US$), 2011 - 2016
  • Figure 8-6: Italy - Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 - 2022
  • Figure 8-7: Italy - Multiple Sclerosis Market (Million US$), 2011 - 2016
  • Figure 8-8: Italy - Forecast for Multiple Sclerosis Market (Million US$), 2017 - 2022
  • Figure 9-1: Spain - Multiple Sclerosis Patient Numbers (Thousand), 2011 - 2016
  • Figure 9-2: Spain - Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 - 2022
  • Figure 9-3: Spain - Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 - 2016
  • Figure 9-4: Spain - Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 - 2022
  • Figure 9-5: Spain - Multiple Sclerosis Unmet Market (Million US$), 2011 - 2016
  • Figure 9-6: Spain - Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 - 2022
  • Figure 9-7: Spain - Multiple Sclerosis Market (Million US$), 2011 - 2016
  • Figure 9-8: Spain - Forecast for Multiple Sclerosis Market (Million US$), 2017 - 2022
  • Figure 10-1: United States - Multiple Sclerosis Patient Numbers (Thousand), 2011 - 2016
  • Figure 10-2: United States - Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 - 2022
  • Figure 10-3: United States - Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 - 2016
  • Figure 10-4: United States - Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 - 2022
  • Figure 10-5: United States - Multiple Sclerosis Injectables Patient Numbers (Thousand), 2011 - 2016
  • Figure 10-6: United States - Forecast for Multiple Sclerosis Injectables Patient Numbers (Thousand), 2017 - 2022
  • Figure 10-7: United States - Multiple Sclerosis Infusions Patient Numbers (Thousand), 2011 - 2016
  • Figure 10-8: United States - Forecast for Multiple Sclerosis Infusions Patient Numbers (Thousand), 2017 - 2022
  • Figure 10-9: United States - Multiple Sclerosis Orals Patient Numbers (Thousand), 2011 - 2016
  • Figure 10-10: United States - Forecast for Multiple Sclerosis Orals Patient Numbers (Thousand), 2017 - 2022
  • Figure 10-11: United States - Multiple Sclerosis Unmet Market (Billion US$), 2011 - 2016
  • Figure 10-12: United States - Forecast for Multiple Sclerosis Unmet Market (Billion US$), 2017 - 2022
  • Figure 10-13: United States - Multiple Sclerosis Market (Billion US$), 2011 - 2016
  • Figure 10-14: United States - Forecast for Multiple Sclerosis Market (Billion US$), 2017 - 2022
  • Figure 10-15: United States - Multiple Sclerosis Injectables Market (Million US$), 2011 - 2016
  • Figure 10-16: United States - Forecast for Multiple Sclerosis Injectables Market (Million US$), 2017 - 2022
  • Figure 10-17: United States - Multiple Sclerosis Infusions Market (Million US$), 2011 - 2016
  • Figure 10-18: United States - Forecast for Multiple Sclerosis Infusions Market (Million US$), 2017 - 2022
  • Figure 10-19: United States - Multiple Sclerosis Orals Market (Million US$), 2011 - 2016
  • Figure 10-20: United States - Forecast for Multiple Sclerosis Orals Market (Million US$), 2017 - 2022
  • Figure 12-1: Europe - Number of Neurologists per 100,000 Specialized in MS vs. Percent of MS Population Receiving DMDs, 2013

List of Tables

  • Table 11-1: Europe - Reimbursements for Disease Modifying Drugs (DMDs), 2013
Back to Top